Trials / Completed
CompletedNCT03559647
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 358 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA). |
Timeline
- Start date
- 2018-05-30
- Primary completion
- 2023-08-20
- Completion
- 2023-08-20
- First posted
- 2018-06-18
- Last updated
- 2023-09-01
Locations
94 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03559647. Inclusion in this directory is not an endorsement.